Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23342647 | 0.83 | CA14 (0.36) | CA14CA12CA1CA2DGAT1 | |
| SCHEMBL21974201 | 0.83 | CTSK (0.38) | CA14CA12CA1CA2DGAT1 | |
| SCHEMBL16547233 | 0.83 | CA14 (0.35) | CA14CA12CA1CA2DGAT1 | |
| SCHEMBL31757775 | 0.83 | CA14 (0.34) | CA14CA12CA1CA2DGAT1 | |
| SCHEMBL3099876 | 0.83 | CA14 (0.34) | CA14CA12CA1CA2DGAT1 | |
| SCHEMBL17898137 | 0.82 | MEN1 (0.34) | CA14CA12CA1CA2CA7 | |
| SCHEMBL10473405 | 0.82 | MEN1 (0.34) | CA14CA12CA1CA2CA7 | |
| SCHEMBL31757748 | 0.81 | CA14 (0.33) | CA14CA12CA1CA2DGAT1 | |
| SCHEMBL16547232 | 0.81 | CA1 (0.34) | CA14CA12CA1CA2DGAT1 | |
| SCHEMBL22562188 | 0.80 | CA14 (0.33) | CA14CA12CA1CA2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | ANPEP, NPEPPS, PEPD | CA14 3895/4885CA12 3720/4885CA1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.